Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351537 | 0.91 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL4216922 | 0.89 | ALDH1A1 (0.51) | ALDH1A1LMNANPC1RAB9AHSD17B1 | |
| SCHEMBL4216929 | 0.89 | ALDH1A1 (0.51) | ALDH1A1LMNANPC1RAB9AHSD17B1 | |
| SCHEMBL4210229 | 0.86 | KMT2A (0.44) | HSD17B10LMNACYP19A1KMT2ASMN1; SMN2 | |
| SCHEMBL4210226 | 0.86 | KMT2A (0.44) | HSD17B10LMNACYP19A1KMT2ASMN1; SMN2 | |
| SCHEMBL4695567 | 0.86 | KMT2A (0.44) | HSD17B10LMNACYP19A1KMT2ASMN1; SMN2 | |
| SCHEMBL4185400 | 0.83 | CYP19A1 (0.44) | NPC1RAB9ACYP19A1CCR1BRD4 | |
| SCHEMBL4193569 | 0.83 | CYP19A1 (0.44) | NPC1RAB9ACYP19A1CCR1BRD4 | |
| SCHEMBL6211946 | 0.82 | CCR1 (0.47) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL6206966 | 0.79 | ALDH1A1 (0.44) | KDM4EALDH1A1HPGDHSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041905-A1 | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | claimed |
| EP-2044045-A2 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-ACETYLAMINO-ALKOXYPHENYL | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | claimed |
| EP-2027105-A2 | NOVEL PROCESS FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | claimed |
| WO-2008010764-A2 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-ACETYLAMINO-ALKOXYPHENYL | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | claimed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20100041905-A1 | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041905-A1 | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041905-A1 | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| EP-2044045-A2 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-ACETYLAMINO-ALKOXYPHENYL | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009035407-A1 | USE OF INTERMEDIATES ((R ) -2,2, 4-TRIMETHYL-L, 3-DIOXOLANE-4-YL) METHANOL (A), 3-F LUORO-4-NITRO-PHENOL (B) AND 1- (4-CHLORO- BENZYL) -PIPERIDIN-4-YLAMINE (C) | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| EP-2027105-A2 | NOVEL PROCESS FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| WO-2008010764-A2 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-ACETYLAMINO-ALKOXYPHENYL | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008010764-A2 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-ACETYLAMINO-ALKOXYPHENYL | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064884-A1 | Novel Process 1 | TPX2, UGT1A1, BRIX1 | KDM4E 2494/4885ALDH1A1 294/4885HPGD 1613/4885 |
| US-20100041905-A1 | Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl | F12, RPS4Y1, CCNA1 | KDM4E 989/4885ALDH1A1 126/4885HPGD 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.